- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06802172
Effect of Time-Restricted Eating During Cancer Treatment in Alaska Native Patients with Rectal Cancer
Effect of Meal Timing During Cancer Treatment in Alaska Native Patients: a Randomized Clinical Trial
The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response and metabolic health in an understudied population. This clinical trial will enroll patients with rectal cancer receiving neoadjuvant treatment at the Alaska Native Medical Center (ANMC), which is part of the Alaska Native Tribal Health Consortium (ANTHC).
A promising strategy for improving the efficacy of anticancer treatments and reducing associated toxicities involves combining treatment with fasting regimens. In pre-clinical and clinical studies, various forms of fasting have been shown to induce tumor regression and improve long-term survival. According to the differential stress sensitization theory, fasting is thought to sensitize tumor cells to the cytotoxic effects of chemotherapy and radiation, while protecting healthy cells by increasing stress resistance. While healthy cells slow their growth and become more stress resistant in response to fasting, cancer cells cannot survive in nutrient-deficient environments; although the underlying mechanisms are not fully understood. However, extended water-only fasting can be challenging for patients and poses undue health risks. Intermittent fasting, and specifically time-restricted eating (TRE), may offer a viable alternative. TRE involves eating within a shorter window (e.g., 8 hours) and fasting for the remainder of the day but involves no other dietary restrictions. Because of its simplicity, TRE may be more sustainable than other fasting regimens. TRE also improves several cardio-metabolic endpoints, including insulin sensitivity, which may also be beneficial during anticancer treatments.
Study Overview
Status
Conditions
Detailed Description
Participants will be randomized to one of two groups:
- Time-restricted eating (TRE) (8-hour daily eating period, starting 1-3 hours after waking up), OR
- A control group defined as a ≥12-hour daily eating period.
Participants are assigned to either TRE (8-hour daily eating period, starting 1-3 hours after waking up) or a control group defined as a ≥12-hour daily eating period. Their randomized meal assignment arm begins no later than 1-2 week after they begin cancer treatment and ends at end of treatment (resection if indicated). This is a period of approximately 6 months.
During this time, participants will be asked to record the time they started and finished eating every day. Electronic reminders and weekly calls to the participants will be made by study staff who maintain records of patient's meal timing. Researchers will time the TRE schedules relative to sleep time (not time of day), which is a reasonable proxy for circadian time. The control group was designed to mimic typical eating habits in the U.S., as data from NHANES suggest that the median American eats over a 12.5-hour period each day. Aside from these general prescriptions, no set number of snacks, meals, or calories will be prescribed. Instead, researchers will measure how TRE affects self-reported mealtimes, meal frequency, and food intake through a combination of daily adherence surveys, 3-day food records and continuous glucose monitoring (CGM).
Participants will receive weekly one-on-one nutrition counseling during the first month and then monthly counseling sessions thereafter. Participants will complete questionnaires at intake and subsequent follow-up assessments. Blood and stool samples will also be collected from participants throughout the study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Timothy Thomas, MD
- Phone Number: (907) 729-3095
- Email: tkthomas@anthc.org
Study Locations
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Alaska Native Medical Center (ANMC)
-
Contact:
- Timothy Thomas, MD
- Phone Number: (907) 729-3095
- Email: tkthomas@anthc.org
-
Contact:
- Timothy Thomas, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female
- Self-identify as Alaska Native or American Indian person and eligible for care at the Alaska Native Medical Center
- Age ≥ 21 years
- Histologically confirmed rectal cancer stage II or III per AJCC criteria
- BMI≥18.5 kg/m2
- Plan to receive either neoadjuvant conventional chemoradiation or total neoadjuvant therapy (TNT) with 5-fluorouracil-based regimens
- Demonstrate adequate organ and marrow function within two weeks of study treatment initiation
- Must have capacity to give informed consent
- Willing and able to adhere to the assessments, visit schedules, prohibitions, and restrictions
Exclusion Criteria:
- Prior neoadjuvant or adjuvant chemotherapy/radiation <12 months prior to rectal cancer occurrence
- Allergic reaction to any of the treatment agents
- Any prior pelvic radiotherapy or chemoradiotherapy
- Major surgery/open biopsy ≤4 weeks prior to enrollment or minor surgery/core biopsy ≤1 week prior to enrollment
- Currently active second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ
- History of GI perforation ≤12 months prior to enrollment
- History of malabsorption, uncontrolled vomiting or diarrhea, or other GI-function affecting disease
- History of predisposing colonic or small bowel disorders with uncontrolled symptoms
- Receiving any parenteral nutrition or enteral (tube) feeding or using any other nutritional supplement during the study period
- History of uncontrolled CHF defined as NYHA Class III or greater
- Uncontrolled hypertension
- History of bleeding events, bleeding diathesis, arterial thrombotic events (including TIA, CVA, unstable angina requiring intervention, or MI), or clinically significant PAD and ≤6 months prior to enrollment
- Pre-existing grade ≥3 neuropathy
- Currently participating in or has participated in a study of an investigational agent or investigational device ≤4 weeks of the first dose of treatment
- Unstable psychiatric, sleep, or circadian conditions (common conditions such as sleep apnea and depression are acceptable as long as they are stabilized and not rapidly worsening)
- Pregnant or breastfeeding
- Currently perform overnight shift work more than one day/week on average
- Regularly eat within an <11-hour period each day
- Known psychiatric or substance misuse disorders that would interfere with adhering to the requirements of the trial
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation in the trial, or is not in the best interest of the participant to participate, in the opinions of the treating investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Time-restricted eating (TRE)
Participants assigned to the TRE group will have an 8-hour daily eating period, starting 1-3 hours after waking up [8 hours eating / 16 hours fasting per day (6+ days a week)].
|
Complete questionnaire
Undergo collection of blood and stool
Participate in time-restricted eating plan
Receive nutrition counseling
|
Active Comparator: Control group
Participants assigned to the control group are not time-restricted, and have a 12+ hour window of eating per day.
|
Complete questionnaire
Undergo collection of blood and stool
Receive nutrition counseling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Complete Response (pCR) rate
Time Frame: At completion of neoadjuvant treatment (6 months)
|
The pCR will be defined as an absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected rectal specimen and all sampled regional lymph nodes.
It will be treated as a binary variable.
|
At completion of neoadjuvant treatment (6 months)
|
Treatment-related toxicity
Time Frame: From enrollment till completion of neoadjuvant treatment (6 months)
|
The Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE v.5) measurement system will be used to measure treatment-related toxicities.
The PRO-CTCAE will be administered on a weekly basis throughout the intervention and will calculate the average over all items for each time point.
Surveys will be timed relative to the start of each oncologic treatment segment.
|
From enrollment till completion of neoadjuvant treatment (6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Complete Response (cCR)
Time Frame: At completion of neoadjuvant treatment (6 months)
|
A cCR will be defined as the clinical absence of residual disease on physical examination, endoscopic examination, and/or repeat MRI imaging following completion of total neoadjuvant treatment.
|
At completion of neoadjuvant treatment (6 months)
|
Tumor volume
Time Frame: From baseline to surgery (approximately 6 months)
|
Standard of care CT and MRI images will be obtained at the time of diagnosis for staging.
A repeat standard of care MRI imaging may be obtained prior to surgery to assess response to neoadjuvant therapy and to guide clinical and surgical management.
Researchers will obtain routine clinical restaging scans from participants and use them to estimate changes in tumor volume between the two time points.
|
From baseline to surgery (approximately 6 months)
|
Objective response rate (ORR)
Time Frame: At the time of surgery (approximately 6 months/days)
|
The ORR is defined as the percentage of people who have a partial response (defined as a decrease in tumor volume) or a complete response to treatment between enrollment and surgery.
|
At the time of surgery (approximately 6 months/days)
|
Adherence
Time Frame: From enrollment till completion of study participation (6 months)
|
Adherence will be defined as at least 70% of the daily regimen followed (for example, eating <8 hours for 6 or more days per week on average during the 6-month treatment period).
Participants will be asked to self-report their adherence using a weekly survey, which asks participants to record the time they start and finish eating each day and to document any reasons for non-adherence.
|
From enrollment till completion of study participation (6 months)
|
Health-related quality of life (HR-QOL)
Time Frame: From enrollment till completion of neoadjuvant treatment (6 months)
|
We will use the widely-used and validated European Organization for Research and Treatment of Cancer Quality of Life (QOL) core questionnaire C30 (EORTC QLQ-C30) and the colorectal-cancer specific questionnaire (EORTC CR29).
For this study, we focus on highly prevalent rectal cancer treatment-related symptoms, including fatigue, insomnia, pain and bowel-related items (stool frequency, flatulence, and fecal incontinence).
|
From enrollment till completion of neoadjuvant treatment (6 months)
|
Neoadjuvant rectal (NAR) score
Time Frame: At completion of neoadjuvant treatment (6 months)
|
The NAR score is a validated surrogate endpoint for oncologic outcomes used in rectal cancer clinical trials.
It takes as input the pathologic nodal status and the clinical and pathologic T-stage.
|
At completion of neoadjuvant treatment (6 months)
|
Provider-reported adverse events
Time Frame: From enrollment till completion of neoadjuvant treatment (6 months)
|
As secondary measures of toxicity, researchers will collect provider-reported adverse event data.
Researchers will analyze the incidence of grade 3-4 toxicities and calculate the aggregated Toxicity Index (TI).
The TI accounts for the frequency and cumulative burden of all toxicities during the treatment period.
|
From enrollment till completion of neoadjuvant treatment (6 months)
|
Progression-free survival (PFS)
Time Frame: 12- and 24 months post completion of neoadjuvant treatment and surgery
|
12- and 24 months post completion of neoadjuvant treatment and surgery
|
|
Relapse-free survival (RFS)
Time Frame: 12- and 24 months post completion of neoadjuvant treatment and surgery
|
12- and 24 months post completion of neoadjuvant treatment and surgery
|
|
Overall survival (OS)
Time Frame: 12- and 24 months post completion of neoadjuvant treatment and surgery
|
12- and 24 months post completion of neoadjuvant treatment and surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Timothy Thomas, MD, Alaska Native Tribal Health Consortium (ANTHC)
- Principal Investigator: Jane Figueiredo, PhD, M.Sc., Cedars-Sinai Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RG1124486
- 1P50CA285275-01A1 (U.S. NIH Grant/Contract)
- 2111923-7 (Other Identifier: Alaska Area Institutional Review Board (AAIRB))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer Stage II
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedStage I Colon Cancer | Stage I Rectal Cancer | Stage II Colon Cancer | Stage II Rectal Cancer | Stage III Colon Cancer | Stage III Rectal CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingStage III Rectal Cancer AJCC V8 | Stage I Rectal Cancer AJCC V8 | Stage II Rectal Cancer AJCC V8 | Stage I Colon Cancer AJCC V8 | Stage II Colon Cancer AJCC V8 | Stage III Colon Cancer AJCC V8United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Rectum | Stage I Colon Cancer | Stage I Rectal Cancer | Stage II Colon Cancer | Stage II Rectal Cancer | Stage III Colon Cancer | Stage III Rectal Cancer | Adenocarcinoma of the ColonUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC V8 | Stage IIB Rectal Cancer AJCC V8 | Stage III Rectal Cancer AJCC V8 | Stage IIIA Rectal Cancer AJCC V8 | Stage IIIB Rectal Cancer AJCC V8 | Stage IIIC Rectal Cancer AJCC V8 | Stage II Rectal Cancer AJCC V8 | Stage IIC Rectal Cancer AJCC V8United States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerRectal Adenocarcinoma | Stage IV Rectal Cancer AJCC V8 | Stage IIA Rectal Cancer AJCC V8 | Stage IIB Rectal Cancer AJCC V8 | Stage III Rectal Cancer AJCC V8 | Stage IIIA Rectal Cancer AJCC V8 | Stage IIIB Rectal Cancer AJCC V8 | Stage IIIC Rectal Cancer AJCC V8 | Stage IVA Rectal Cancer AJCC V8 | Stage... and other conditionsUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingFinancial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing TreatmentStage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IIA Rectal Cancer AJCC... and other conditionsUnited States
-
Peking University Third HospitalRecruitingRectal Cancer Stage II | Rectal Cancer Stage IIIChina
-
Prof. Dr. med. Claus RödelJohann Wolfgang Goethe University Hospital; Deutsche Krebshilfe e.V., Bonn...CompletedRectal Neoplasms | Rectal Cancer Stage II | Rectal Cancer Stage IIIGermany
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingInvasive Breast Carcinoma | COVID-19 Infection | Breast Ductal Carcinoma in Situ | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation